MOTS-c
Mitochondrial-derived peptide · 16 amino acids
A mitochondrial-derived peptide encoded in mitochondrial DNA, studied for metabolic regulation and exercise mimicry effects.

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA rather than nuclear DNA — making it one of the first mitochondrially derived peptides shown to have systemic hormonal effects. Discovered in 2015 by a team at the University of Southern California led by Pinchas Cohen, MOTS-c is essentially a hormone made by your mitochondria that tells the rest of your body how to handle fuel. Its levels decline with age, and researchers believe this decline contributes to age-related metabolic dysfunction. The name stands for Mitochondrial Open Reading Frame of the 12S rRNA-c — not catchy, but the biology is significant.
MOTS-c operates primarily through the AMPK (AMP-activated protein kinase) pathway, the cell's fuel gauge that activates when cellular energy is low. When MOTS-c activates AMPK, glucose uptake into cells increases, fatty acid oxidation ramps up, insulin sensitivity improves, and mitochondrial biogenesis is stimulated — cells produce more mitochondria, expanding their overall energy capacity. Under stress conditions, MOTS-c also translocates to the nucleus and regulates gene expression related to metabolic adaptation, suggesting a deeper role in how the body responds to exercise and caloric restriction. Crucially, glucose gets directed preferentially into muscle tissue rather than fat tissue, meaning more of what you eat fuels performance and less gets stored.
The subjective experience centers on endurance and sustained output rather than stimulant-like energy. The effects build over 2 to 4 weeks. Sets that previously left users gassed become manageable. Cardio sessions that were a grind become sustainable. Recovery between training sessions is faster. Injection site irritation is the most commonly reported side effect due to the peptide's mild acidity — using a 30g needle and injecting slowly reduces this significantly.
Community Experiences
"MOTS-c works. It is almost impossible to find failure when training lower weights for high reps. When hiking with friends I leave them in the dust." — r/Biohackers
"The effect is not about being stronger, it is about being able to sustain effort for longer. I push through sets where I would normally fail — not more force, just more endurance." — r/Biohackers
"Subtle compared to retatrutide. You don't feel a dramatic shift in the first few days. But at week three you realize the workouts are just easier, and recovery is noticeably faster." — r/Retatrutide

Mitochondrial-derived peptide research for metabolic optimization
Frequently Asked Questions
Is MOTS-c natural? Yes. MOTS-c is produced by your own mitochondria. Levels decline with age, and research is exploring whether restoring those levels can reverse age-related metabolic decline.
How long does MOTS-c take to work? Most researchers report noticeable effects within 2 to 4 weeks of consistent use. Endurance and energy benefits tend to appear before body composition changes.
What is the typical research dose? Research protocols commonly use 5 to 10 mg, administered 5 days per week. Some protocols extend to daily use.
Can MOTS-c help with weight loss? MOTS-c is not a direct weight loss peptide. It improves metabolic efficiency and exercise capacity, which supports weight loss when combined with a caloric deficit and physical activity. It is often stacked with appetite-suppressing peptides like retatrutide for a combined metabolic effect.
Stacking Suggestions
- Retatrutide for combining appetite control with enhanced metabolic output during weight loss
- SS-31 for direct mitochondrial membrane repair alongside MOTS-c's metabolic signaling
- 5-Amino-1MQ for additional metabolic acceleration through a different mechanism
- NAD+ for supporting mitochondrial function at the cofactor level while MOTS-c handles signaling
- BPC-157 for recovery support when training volume increases due to improved capacity
Verified Literature & Trial Registry · NCBI PubMed & ClinicalTrials.gov
MOTS-c: Indexed Studies & Clinical Trials
Evidence & Scope Notice (R06): The records below are retrieved directly from NCBI PubMed and ClinicalTrials.gov. Preclinical (rodent/in vitro) studies do not establish human safety or efficacy. This index is for educational research literacy only and is never medical advice.
Registered Human Clinical Trials (ClinicalTrials.gov)
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Conditions: Diabetes, Clopidogrel Resistance, Amyloid
Primary Endpoint: mots-c predicts cardiovascular mortality in diabetic with coronary artery disease
Cohort Of DEafness-gene Screening
Conditions: Hearing Loss
Primary Endpoint: Diagnosis of hearing loss at age of 3 months
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
Conditions: Diabetes Mellitus, Type 2
Primary Endpoint: Comparison of Global Longitudinal Strain (GLS) difference among treatment groups.
Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation
Conditions: Kidney Disease, End-Stage, Kidney Transplant, Kidney
Primary Endpoint: Serum ferroptosis-related biomarkers (Fe, TFRC1, GPX4, MDA, ACSL4) and mitochondrial-derived peptides (humanin and MOTS-c)
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
Conditions: Prediabetes, Insulin Resistance, Overweight/Obesity
Primary Endpoint: Change from baseline in OGTT-derived insulin sensitivity (Matsuda Index)
Selected Peer-Reviewed PubMed Literature
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Lee C, Zeng J, Drew BG et al. · DOI: 10.1016/j.cmet.2015.02.009
Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases
Kong BS, Lee C, Cho YM · DOI: 10.4093/dmj.2022.0333
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation
Zheng Y, Wei Z, Wang T · DOI: 10.3389/fendo.2023.1120533
The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus
Yin Y, Pan Y, He J et al. · DOI: 10.1016/j.phrs.2021.105987
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Reynolds JC, Lai RW, Woodhead JST et al. · DOI: 10.1038/s41467-020-20790-0
MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases
Mohtashami Z, Singh MK, Salimiaghdam N et al. · DOI: 10.3390/ijms231911991